Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Potassium iodide

This article was originally published in The Tan Sheet

Executive Summary

"FDA is planning to conduct studies of the palatability, solubility and stability of KI dissolved in a number of different liquids, including juice and formula," agency says in Q&A document on use of the OTC in radiation emergencies. FDA notes it is working with KI manufacturers to "expedite submission and review" of applications for tablet dosage strengths below 130 mg and to amend "Drug Facts" labeling to incorporate new KI dosing recommendations announced in December (1"The Tan Sheet" Dec. 17, 2001, p. 5). Recommendations generally call for adults 18 and older to take 130 mg/day, children three and older 65 mg/d, children under three 32 mg/d...

You may also be interested in...



Potassium Iodide Stockpiling Guidelines Called For In Bioterrorism Bill

Within a year of enacting bioterrorism legislation, the Bush Administration will consult with federal, state and local agencies to establish guidelines for the stockpiling of potassium iodide (KI) tablets

Bioterrorism Preparedness Addressed On Capitol Hill, At FDA

Any facility that manufactures, processes, packs or holds food for consumption in the U.S. would have to register with HHS within 180 days of the enactment of a bioterrorism bill passed by the House Dec. 12

Vaccine Experts Inject Realism Into US Gov't's COVID-19 Timeline

The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval. 

Topics

UsernamePublicRestriction

Register

PS093951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel